The Technical AnalystExchange: CPH Sector: Healthcare Industry: Biotechnology
ALK-Abelló A/S Price, Forecast, Insider, Ratings, Fundamentals & Signals
0.00% DKK130.50
America/New_York / 1 mai 2024 @ 07:17
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 29 051 mill |
| EPS: | 2.21 |
| P/E: | 59.05 |
| Earnings Date: | May 03, 2024 |
| SharesOutstanding: | 222.61 mill |
| Avg Daily Volume: | 0.281 mill |
| RATING 2024-05-01 |
|---|
| A |
| Buy |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Buy | |
| Return On Asset: | Buy | |
| DE: | Neutral | |
| P/E: | Strong Buy | |
| Price To Book: | Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 1.23x |
| Company: PE 59.05 | sector: PE 47.95 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 1.46x |
| Company: PE 59.05 | industry: PE 40.56 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
DKK17.57 (-86.54%) DKK-112.93 |
| Date: 2024-05-01 |
| Expected Trading Range (DAY) |
|---|
|
DKK 127.48 - 133.52 ( +/- 2.32%) |
| ATR Model: 14 days |
Live Trading Signals (every 1 min)
10.00
Buy
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | DKK130.50 (0.00% ) |
| Volume | 0.0208 mill |
| Avg. Vol. | 0.281 mill |
| % of Avg. Vol | 7.41 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For ALK-B.CO
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
ALK-B.CO
ALK-Abelló A/S operates as an allergy solutions company in Europe, North America, and internationally. It product portfolio include GRAZAX/GRASTEK, RAGWITEK/RAGWIZAX, ACARIZAX/ODACTRA, MITICURE, CEDACURE, and ITULAZAX for treatment of allergic rhinitis and allergic asthma. The company offers allergy immunotherapy products in the form of injections, sublingual drops, and tablets for the treatment of various allergies, including grass, ragweed, house dust mite, Japanese cedar, tree, and food. It also provides consumer healthcare solution, which include Digital eco-system, a platform which connect and engages with allergy sufferers much earlier in the disease journey through tools and e-commerce offerings that supports, guidance and relief, and smoothing the path to allergy immunotherapy treatment. In addition, the company offers diagnostic allergy solutions through testing by skin prick test or blood test; and emergency treatment, such as intramuscular injection of adrenaline for the treatment of acute life-threatening allergic reactions including Anaphylaxis. ALK-Abelló A/S was founded in 1923 and is headquartered in Hørsholm, Denmark.